Abstract
This article reviews how the criteria for patentability apply to inventions involving human embryonic stem cells in both Australia and Japan, provides an analysis of the current position of the law, and discusses the possible implications in relation to the patenting of human stem cells. It also examines a recent court case, Cancer Voices Australia and another v Myriad Genetics Inc and another, the first judicial decision in Australia to consider the patentability of isolated DNA or Ribonucleic Acid (RNA) sequences that challenged the statutory provisions within the Patents Act 1990 (Cth). This article concludes that Japan is comparatively moderate in granting stem cell patents and has a far less ambiguous approach to stem cell patents than Australia.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Journal of Intellectual Property Law & Practice
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.